财联社7月3日电, 礼来 公司表示,美国食品和药物管理局(FDA)已批准Kisunla用于有 阿尔茨海默 病早期症状的成人患者。6个月的疗程费用为12,522美元,12个月的费用为32,000美元,18个月的费用为48,696美元。
![share_log](https://pubimg.futunn.com/2022050900000225beae9ba9bea.jpg?imageMogr2/thumbnail/76x76!/ignore-error/1/format/webp)
English
Back
- Markets
- Features
- News
- Community
- Learn
- Help Center
- About
- Offers & Rewards
- English
- 繁體中文
- 简体中文
- Dark
- Light
礼来延缓阿尔茨海默病的药物获得美国批准
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.